Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.

CONCLUSIONS: Treatment with dapagliflozin for six months significantly improved glycemic control and reduced body weight without reducing muscle mass in T2DM patients. PMID: 29225209 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research